STOCK TITAN

CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Cellyan Biotechnology (Nasdaq: HKPD) regained compliance with Nasdaq’s minimum bid price requirement, resolving its previously disclosed listing deficiency.

Nasdaq confirmed compliance in a written notification received on November 13, 2026. The company’s Class A ordinary shares maintained a closing bid price of at least US$1.00 for 14 consecutive business days, from October 26 through November 12, 2026. Nasdaq closed the matter. The original deficiency notice was issued on January 12, 2026, after the shares closed below US$1.00 for 30 consecutive business days. An extension had given the company until January 11, 2027, to regain compliance.

Loading...
Loading translation...
1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointNasdaq minimum bid price compliance regained; the matter was closed following 14 consecutive business days at or above US$1.00.

Negative

  • None.

Key Figures

Minimum closing bid price: at least US$1.00 per share Compliance period achieved: 14 consecutive business days Required compliance duration: 10 consecutive business days
Minimum closing bid price
at least US$1.00 per share
Nasdaq minimum bid price requirement
Compliance period achieved
14 consecutive business days
October 26 through November 12, 2026
Required compliance duration
10 consecutive business days
Minimum period at or above the required bid price

Historical Context

2 past events · Latest: Oct 21
2 events
  1. Oct 21

    Reverse stock split

    24h Move
    -8.9%

    Announced a planned 1-for-20 reverse split as a compliance measure.

  2. Jul 16

    Nasdaq extension

    24h Move
    -11.7%

    Received an additional compliance period through January 11, 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market.

As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company’s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, as a result, the Company was not in compliance with the Minimum Bid Price Requirement. Nasdaq provided the Company with an initial compliance period of 180 calendar days, or until July 13, 2026, to regain compliance. To regain compliance, the Company was required to maintain a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period. On July 14, 2026, the Company received written notice from Nasdaq granting an additional 180 calendar days, or until January 11, 2027, to regain compliance with the Minimum Bid Price Requirement.

Subsequently, on November 13, 2026, Nasdaq determined that the closing bid price of the Company’s Class A ordinary shares was at least US$1.00 per share for the 14 consecutive business days from October 26 through November 12, 2026. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter was closed.

About Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.

For investor and media inquiries please contact: 

Cellyan Biotechnology Co., Ltd
Media Contact: andy@cell-yan.com  
Investor Relations: stella@cell-yan.com 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Cellyan Biotechnology (HKPD) regain Nasdaq bid price compliance?

Cellyan’s Class A ordinary shares maintained a closing bid price of at least US$1.00 for 14 consecutive business days, from October 26 through November 12, 2026. Nasdaq confirmed compliance on November 13, 2026, and closed the matter.

Keep reading